Trial intelligence / Profile preview

PhageBank Therapy for Chronic Prosthetic Joint Infection

NCT05269121Phase 2Withdrawn

Sponsor
BiomX
Start
Sep 2022
Primary completion
Nov 2023
Modality
Single Strain Products, Multi-strain Products
01

Overview

A Phase 2 trial of PhageBank in prosthetic joint infection (PJI), sponsored by BiomX. Planned start Sep 2022; status: withdrawn.

02

Drugs

PhageBank
03

Conditions

prosthetic joint infection (PJI)

Beyond the preview

Go deeper on NCT05269121.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05269121.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call